Abstract:The aim of this study was to explore the effects and mechanism of mogroside on postprandial and fasting blood glucose control in diabetic mice.Male mice were randomly divided into normal，model，pioglitazone，and mogroside （high-dose and low-dose）groups.A high-fat diet combined with low-dose streptozotocin injection was used to induce diabetic model while normal mice fed with high and low doses of mogroside were used as controls.The effects and mechanisms of mogroside on glucose control in diabetic animals were studied by measuring intestinal α -glucosidase activity，detecting plasma insulin （INS）and glucagon-like peptide-1 （GLP-1）levels，and performing oral glucose tolerance tests （OGTT）and fasting blood glucose （FBG）tests.The results of this study revealed that mogroside had no effect on intestinal αglucosidase activity in normal mice but significantly reduced intestinal α-glucosidase activity in diabetic mice（P<0.05），while alleviating excessive increases in postprandial glycemia in diabetic mice.In addition，the GLP-1 levels in the high-and low-dose mogroside groups were higher than those in the model group（P<0.01）.Moreover，the plasma insulin levels in the high-dose mogroside group were significantly higher than those in the model group（P<0.01）.These results suggest that mogroside may enhance blood glucose control in diabetic mice by inhibiting intestinal α-glucosidase activity and promoting the levels of glucagon-like peptide-1，which in turn increases insulin secretion.